Yasuji Arase

Summary

Affiliation: Toranomon Hospital
Country: Japan

Publications

  1. ncbi Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C
    Yasuji Arase
    Department of Hepatology and Okinaka Memorial Institute for Medical Research, Toranomon Hospital, Tokyo, Japan
    Hepatology 57:964-73. 2013
  2. ncbi Interferon therapy for 2 years or longer reduces the incidence of hepatocarcinogenesis in patients with chronic hepatitis C viral infection
    Yasuji Arase
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Intervirology 47:355-61. 2004
  3. ncbi Combination therapy of peginterferon and ribavirin for chronic hepatitis C patients with genotype 1b and low-virus load
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Tokyo
    Intern Med 48:253-8. 2009
  4. ncbi Long-term presence of HBV in the sera of chronic hepatitis B patients with HBsAg seroclearance
    Yasuji Arase
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Intervirology 50:161-5. 2007
  5. ncbi Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C
    Yasuji Arase
    Department of Gastroenterology, and Hepatic Research Unit, Toranomon Hospital, Toranomon, Tokyo, Japan
    Intervirology 50:16-23. 2007
  6. ncbi Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Hepatology 49:739-44. 2009
  7. ncbi Efficacy in patients with dose reduction in combination therapy of peginterferon and ribavirin for chronic hepatitis C
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Intervirology 51:1-6. 2008
  8. ncbi Prolonged-efficacy of bisphosphonate in postmenopausal women with osteoporosis and chronic liver disease
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Minato ku, Tokyo, Japan
    J Med Virol 80:1302-7. 2008
  9. ncbi Hepatitis C virus enhances incidence of idiopathic pulmonary fibrosis
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Minato ku, Tokyo 105 8470, Japan
    World J Gastroenterol 14:5880-6. 2008
  10. ncbi Significance of serum ribavirin concentration in combination therapy of interferon and ribavirin for chronic hepatitis C
    Yasuji Arase
    Department of Gastroenterology, Toranomon Hospital, Toranomon, Minato ku, Tokyo, Japan
    Intervirology 48:138-44. 2005

Detail Information

Publications95

  1. ncbi Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C
    Yasuji Arase
    Department of Hepatology and Okinaka Memorial Institute for Medical Research, Toranomon Hospital, Tokyo, Japan
    Hepatology 57:964-73. 2013
    ..7-fold enhancement in the development of HCC and malignancies other than HCC in HCV-positive patients treated with IFN. In T2DM patients, maintaining a mean HbA1c level of <7.0% reduces the development of HCC...
  2. ncbi Interferon therapy for 2 years or longer reduces the incidence of hepatocarcinogenesis in patients with chronic hepatitis C viral infection
    Yasuji Arase
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Intervirology 47:355-61. 2004
    ....
  3. ncbi Combination therapy of peginterferon and ribavirin for chronic hepatitis C patients with genotype 1b and low-virus load
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Tokyo
    Intern Med 48:253-8. 2009
    ..The aim of this study was to evaluate the efficacy of combination therapy of peginterferon and ribavirin in patients infected with hepatitis C virus (HCV) genotype 1b and low virus load...
  4. ncbi Long-term presence of HBV in the sera of chronic hepatitis B patients with HBsAg seroclearance
    Yasuji Arase
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Intervirology 50:161-5. 2007
    ..The aim of this study was to elucidate the presence of serum hepatitis B virus (HBV) DNA at a prolonged time after seroclearance of hepatitis B surface antigen (HBsAg)...
  5. ncbi Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C
    Yasuji Arase
    Department of Gastroenterology, and Hepatic Research Unit, Toranomon Hospital, Toranomon, Tokyo, Japan
    Intervirology 50:16-23. 2007
    ..The purpose of this study was to elucidate the long-term outcome after interferon (IFN) therapy in chronic hepatitis C elderly patients...
  6. ncbi Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Hepatology 49:739-44. 2009
    ..10; 95% CI 1.38-3.18; P < 0.001). CONCLUSION: Our results indicate sustained virological response causes a two-thirds reduction in the risk of type 2 diabetes development in HCV-positive patients treated with IFN...
  7. ncbi Efficacy in patients with dose reduction in combination therapy of peginterferon and ribavirin for chronic hepatitis C
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Intervirology 51:1-6. 2008
    ..The aim of this study was to elucidate efficacy after dose reduction in combination therapy of peginterferon and ribavirin for chronic hepatitis C...
  8. ncbi Prolonged-efficacy of bisphosphonate in postmenopausal women with osteoporosis and chronic liver disease
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Minato ku, Tokyo, Japan
    J Med Virol 80:1302-7. 2008
    ..2% at the second year, and 57.6% at the fifth year. The present study suggests that a serum albumin level of >or=3.5 g/dl and cyclic etidronate treatment reduce the appearance of bone fracture...
  9. ncbi Hepatitis C virus enhances incidence of idiopathic pulmonary fibrosis
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Minato ku, Tokyo 105 8470, Japan
    World J Gastroenterol 14:5880-6. 2008
    ..To investigate the cumulative development incidence and predictive factors for idiopathic pulmonary fibrosis in hepatitis C virus (HCV) positive patients...
  10. ncbi Significance of serum ribavirin concentration in combination therapy of interferon and ribavirin for chronic hepatitis C
    Yasuji Arase
    Department of Gastroenterology, Toranomon Hospital, Toranomon, Minato ku, Tokyo, Japan
    Intervirology 48:138-44. 2005
    ..The purpose of this clinical retrospective cohort study was to determine the most suitable ribavirin concentration on combination therapy of interferon (IFN)-ribavirin...
  11. ncbi The efficacy of 24-week interferon monotherapy for type C liver cirrhosis in Japanese patients with genotype 1b and low virus load
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Intervirology 51:265-9. 2008
    ..The aim of this study was to elucidate the efficacy of interferon (IFN) therapy in liver cirrhosis Japanese patients with genotype 1b and low virus load...
  12. ncbi Serum KL-6 level is elevated in chronic hepatitis C patients with combination therapy of pegylated interferon and ribavirin
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Tokyo
    Intern Med 46:1155-60. 2007
    ..The aim of this study was to evaluate whether or not combination therapy of pegylated interferon (IFN) and ribavirin for chronic hepatitis (CH) C patients enhances the serum level of KL-6, a sensitive marker for interstitial pneumonia...
  13. ncbi Usefulness of the serum KL-6 assay in patients with hepatitis C virus
    Yasuji Arase
    Department of Gastroenterology and Hepatic Research Unit, Toranomon Hospital, Tokyo, Japan
    Intervirology 48:400-4. 2005
    ..The aim of this study is to evaluate the serum level of KL-6 in hepatitis C virus (HCV)-positive patients with chronic liver disease...
  14. ncbi Comparison of interferon and lamivudine treatment in Japanese patients with HBeAg positive chronic hepatitis B
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 79:1286-92. 2007
    ..002). Our results suggest that (1) IFN and LMV are the similar effect on response, (2) IFN therapy is more effective for younger patients...
  15. ncbi Suitable treatment period in patients with virological response during combination therapy of peginterferon and ribavirin for chronic hepatitis C
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Tokyo
    Intern Med 47:1301-7. 2008
    ..The aim of this study was to determine the suitable treatment period in patients who achieve virological response during combination therapy of peginterferon and ribavirin for chronic hepatitis C virus infection...
  16. ncbi The efficacy of short-term interferon-beta therapy for type C cirrhotic patients with genotype 2a and low virus load
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Tokyo
    Intern Med 47:1085-90. 2008
    ..The aim of this study was to elucidate the efficacy of short-term interferon (IFN) therapy for type C cirrhotic patients with genotype 2a and low virus load...
  17. ncbi Side effects of combination therapy of peginterferon and ribavirin for chronic hepatitis-C
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Tokyo
    Intern Med 46:1827-32. 2007
    ..The aim of this study was to elucidate the side effects after combination therapy of peginterferon and ribavirin for Japanese patients with chronic hepatitis C...
  18. ncbi Multivariate analysis of risk factors for the development of type 2 diabetes in nonalcoholic fatty liver disease
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, 2 2 2 Toranomon, Minato ku, Tokyo 105 8470, Japan
    J Gastroenterol 44:1064-70. 2009
    ..The aim of this retrospective cohort study was to assess the cumulative development of type 2 diabetes and predictive factors for its development in Japanese patients with NAFLD...
  19. ncbi Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients
    Yasuji Arase
    Department of Hepatology and Okinaka Memorial Institute for Medical Research, Toranomon Hospital, Japan
    Intern Med 50:2083-8. 2011
    ....
  20. ncbi Viral hepatitis: Impact of adherence to combination therapy for hepatitis C
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, 2 2 2 Toranomon, Minato ku, Tokyo, Japan
    Nat Rev Gastroenterol Hepatol 8:248-9. 2011
    ..A prospective, real-time, observational study by Marcellin and colleagues provides useful information for physicians regarding the role of patient adherence in tailoring patient management and optimizing treatment outcomes...
  21. ncbi The development of chronic kidney disease in Japanese patients with non-alcoholic fatty liver disease
    Yasuji Arase
    Department of Hepatology and Okinaka Memorial Institute for Medical Research, Toranomon Hospital, Japan
    Intern Med 50:1081-7. 2011
    ..2%. Five factors of low eGFR level, aging, type 2 diabetes, hypertension, and elevated gamma-glutamyltransferase, increases the risk of the development of CKD...
  22. ncbi Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Toranomon, Minato ku, Tokyo, Japan
    J Med Virol 79:1485-90. 2007
    ..026). The relative risk of HCC development in patients with BR was 0.36 compared with patients without BR. The attainment of BR during IFN therapy is effective in reducing hepatocarcinogenesis for patients with chronic HCV infection...
  23. ncbi Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients with genotype 2 and high virus load
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Intern Med 49:965-70. 2010
    ..The aim of this study was to evaluate the efficacy of combination therapy of natural human interferon-beta and ribavirin in patients infected with hepatitis C virus (HCV) genotype 2 and high virus load...
  24. ncbi Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients with genotype 1b and high virus load
    Yasuji Arase
    Department of Hepatology and Okinaka Memorial Institute for Medical Research, Toranomon Hospital, Tokyo, Japan
    Intern Med 49:957-63. 2010
    ..The aim of this study was to evaluate the efficacy of combination therapy of natural human interferon-beta and ribavirin in patients infected with hepatitis C virus (HCV) genotype 1b...
  25. ncbi Prolonged-interferon therapy reduces hepatocarcinogenesis in aged-patients with chronic hepatitis C
    Yasuji Arase
    Department of Gastroenterology, Toranomon Hospital, 2 2 2 Toranomon, Minato ku, Tokyo, Japan
    J Med Virol 79:1095-102. 2007
    ..9 compared with mild or moderate fibrosis. In conclusion, long-term IFN therapy for aged patients with chronic HCV infection is effective in decreasing the serum AFP level and preventing hepatocarcinogenesis...
  26. ncbi Virus clearance reduces bone fracture in postmenopausal women with osteoporosis and chronic liver disease caused by hepatitis C virus
    Yasuji Arase
    Department of Hepatology and Okinaka Memorial Institute for Medical Research Toranomon Hospital, Tokyo, Japan
    J Med Virol 82:390-5. 2010
    ..J. Med. Virol. 82:390-395, 2010. (c) 2010 Wiley-Liss, Inc...
  27. ncbi Sustained negativity for HCV-RNA over 24 or more months by long-term interferon therapy correlates with eradication of HCV in patients with hepatitis C virus genotype 1b and high viral load
    Yasuji Arase
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Intervirology 47:19-25. 2004
    ..We assessed whether sustained negativity for HCV-RNA over 24 or more months by long-term interferon (IFN) therapy correlates with eradication of HCV in patients with hepatitis C virus genotype 1b and high viral load or not...
  28. ncbi Losartan reduces the onset of type 2 diabetes in hypertensive Japanese patients with chronic hepatitis C
    Yasuji Arase
    Department of Hepatology, Okinaka Memorial Institute for Medical Research, Toranomon Hospital, Tokyo, Japan
    J Med Virol 81:1584-90. 2009
    ..004), and patient had pre-diabetes (hazard ratio: 2.47; 95% confidence interval = 1.08-5.63; P = 0.032). Our results indicate losartan causes about 60% reduction of the onset of T2DM compared to patients treated with spironolactone...
  29. ncbi The efficacy of interferon-beta monotherapy for elderly patients with type C hepatitis of genotype 2
    Yasuji Arase
    Department of Hepatology and Okinaka Memorial Institute for Medical Research, Toranomon Hospital, Tokyo
    Intern Med 48:1337-42. 2009
    ..The aim of this study was to elucidate the efficacy of interferon (IFN)-beta monotherapy for elderly patients of > or = 70 years with type C hepatitis (HCV) of genotype 2...
  30. ncbi Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B
    Yasuji Arase
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Am J Med 119:71.e9-16. 2006
    ..The aim of this study was to elucidate the long-term outcome after hepatitis B surface antigen (HBsAg) seroclearance in a large number of Japanese patients...
  31. ncbi Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 79:1686-95. 2007
    ..This study identified predictors of efficacy of PEG-IFN-RBV therapy based on viral kinetics in Japanese patients infected with HCV genotype 1b...
  32. ncbi A long-term glycyrrhizin injection therapy reduces hepatocellular carcinogenesis rate in patients with interferon-resistant active chronic hepatitis C: a cohort study of 1249 patients
    Kenji Ikeda
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Dig Dis Sci 51:603-9. 2006
    ....
  33. ncbi Substitution of amino acid 70 in the hepatitis C virus core region of genotype 1b is an important predictor of elevated alpha-fetoprotein in patients without hepatocellular carcinoma
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 80:1354-62. 2008
    ..The results highlight the importance of eradication of mutant type virus of aa 70 for reducing the risk of hepatocarcinogenesis...
  34. ncbi Prediction of response to pegylated interferon and ribavirin in hepatitis C by polymorphisms in the viral core protein and very early dynamics of viremia
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Intervirology 50:361-8. 2007
    ..To evaluate power of amino acid polymorphisms in core protein of hepatitis C virus (HCV) for predicting sustained virological response (SVR) to pegylated interferon (Peg-IFN)/ribavirin, when they were combined with virological response...
  35. ncbi Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol l
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Hepatol 46:403-10. 2007
    ..Here, we determined the predictive factors of sustained virological response (SVR) and early virologic response (EVR) to this treatment...
  36. ncbi Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy
    Norio Akuta
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Intervirology 48:372-80. 2005
    ..Non-virological responders (NVRs, namely ultimate resistant cases) who do not achieve HCV-RNA negativity during treatment are also encountered. We investigated the pretreatment virological features of NVRs...
  37. ncbi Efficacy of switching to entecavir monotherapy in Japanese lamivudine-pretreated patients
    Fumitaka Suzuki
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Gastroenterol Hepatol 25:892-8. 2010
    ..To assess the efficacy of switching Japanese chronic hepatitis B patients from lamivudine monotherapy to entecavir 0.5 mg/day...
  38. ncbi A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 81:452-8. 2009
    ..Substitution of aa 70 and 91 is also a useful pretreatment predictor of response to 72-week PEG-IFN/RBV...
  39. ncbi Efficacy of low-dose intermittent interferon-alpha monotherapy in patients infected with hepatitis C virus genotype 1b who were predicted or failed to respond to pegylated interferon plus ribavirin combination therapy
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 80:1363-9. 2008
    ....
  40. ncbi HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy
    Tetsuya Hosaka
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Liver Int 30:1461-70. 2010
    ....
  41. ncbi Influence of amino-acid polymorphism in the core protein on progression of liver disease in patients infected with hepatitis C virus genotype 1b
    Mariko Kobayashi
    Research Institute for Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 82:41-8. 2010
    ....
  42. ncbi Necessities of interferon therapy in elderly patients with chronic hepatitis C
    Kenji Ikeda
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Am J Med 122:479-86. 2009
    ..The significance of antiviral therapy for elderly patients with chronic hepatitis C virus (HCV) infection has not been elucidated...
  43. ncbi Lamivudine monotherapy for spontaneous severe acute exacerbation of chronic hepatitis B
    Akihito Tsubota
    Department of Gastroenterology, Toranomon Hospital, Minato, Tokyo, Japan
    J Gastroenterol Hepatol 20:426-32. 2005
    ..The purpose of the present paper was to identify factors that could influence the rapid progression of liver disease to hepatic failure, and assess the effects of lamivudine on serious disease...
  44. ncbi Virological response and hepatocarcinogenesis in lamivudine-resistant hepatitis B virus genotype C patients treated with lamivudine plus adefovir dipivoxil
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Intervirology 51:385-93. 2008
    ..The long-term efficacy of adefovir dipivoxil in combination with lamivudine to chronic hepatitis B virus (HBV) infection is still unclear...
  45. ncbi Clinicopathological features, background liver disease, and survival analysis of HCV-positive patients with hepatocellular carcinoma: differences between young and elderly patients
    Hiromi Saneto
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Gastroenterol 43:975-81. 2008
    ..The aim of this retrospective study was to determine the incidence and characteristics of hepatocellular carcinoma (HCC) in hepatitis C virus (HCV) antibody-positive elderly patients with chronic hepatitis without cirrhosis...
  46. ncbi Long-term follow-up of interferon monotherapy in 454 consecutive naive patients infected with hepatitis C virus: multi-course interferon therapy may reduce the risk of hepatocellular carcinoma and increase survival
    Norio Akuta
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Scand J Gastroenterol 40:688-96. 2005
    ..The long-term effects of multi-course interferon (IFN) monotherapy in patients infected with hepatitis C virus (HCV) are still unclear...
  47. ncbi Interferon lowers tumor recurrence rate after surgical resection or ablation of hepatocellular carcinoma: a pilot study of patients with hepatitis B virus-related cirrhosis
    Takashi Someya
    Department of Hepatology, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo 105-8470, Japan
    J Gastroenterol 41:1206-13. 2006
    ..21, P = 0.037) even after adjusting for background characteristics. CONCLUSIONS: IFN was inferred to decrease tumor recurrence after treatment of HCC in patients with HBV-related cirrhosis, especially in the subgroup with high AST...
  48. ncbi Amino acid substitution in HCV core region and genetic variation near the IL28B gene affect viral dynamics during telaprevir, peginterferon and ribavirin treatment
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Intervirology 55:417-25. 2012
    ....
  49. ncbi Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years: histological improvement or entecavir resistance?
    Yoshiyuki Suzuki
    Department of Hepatology, Toranomon Hospital, Takatsu ku, Kawasaki City, Japan
    J Gastroenterol Hepatol 24:429-35. 2009
    ..However, hepatitis B virus (HBV) mutants resistant to lamivudine emerge frequently accompanied by breakthrough hepatitis...
  50. ncbi Amino acid substitutions in the hepatitis C virus core region of genotype 1b affect very early viral dynamics during treatment with telaprevir, peginterferon, and ribavirin
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 82:575-82. 2010
    ....
  51. ncbi An open pilot study exploring the efficacy of fluvastatin, pegylated interferon and ribavirin in patients with hepatitis C virus genotype 1b in high viral loads
    Hitomi Sezaki
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Intervirology 52:43-8. 2009
    ..Response to pegylated (PEG) interferon (IFN) and ribavirin is achieved only in 40-50% of patients infected with hepatitis C virus (HCV) of genotype 1 in high viral loads, which needs to be improved...
  52. ncbi Recurrence rate and prognosis of patients with hepatocellular carcinoma that developed after elimination of hepatitis C virus RNA by interferon therapy. A closed cohort study including matched control patients
    Kenji Ikeda
    Department of Gastroenterology, Toranomon Hospital, and Okinaka Memorial Institute for Medical Research, Tokyo, Japan
    Oncology 65:204-10. 2003
    ..Although hepatocellular carcinoma does develop after sustained response to interferon (IFN) in patients with chronic hepatitis C, details on the clinical prognosis have not been elucidated yet...
  53. ncbi Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load
    Norio Akuta
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 78:83-90. 2006
    ....
  54. ncbi Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Hepatology 46:1357-64. 2007
    ..In multicourse IFN therapy to nondouble wild-type, we emphasize the importance of reducing the risk of hepatocarcinogenesis by mean ALT during an IFN-free period below 1.5 times the upper limit of normal...
  55. ncbi Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load
    Akihito Tsubota
    Department of Gastroenterology, Toranomon Hospital, Minato ku, Tokyo, Japan
    J Med Virol 75:27-34. 2005
    ..919. The results suggest that early monitoring of viral kinetics is a useful measure to predict virological response, and might facilitate development of rational and effective therapeutic strategies...
  56. ncbi Hepatocyte steatosis is an important predictor of response to interferon (IFN) monotherapy in Japanese patients infected with HCV genotype 2a: Virological features of IFN-resistant cases with hepatocyte steatosis
    Norio Akuta
    Department of Gastroenterology, Toranomon Hospital, 2 2 2 Toranomon, Minato ku, Tokyo 105 0001, Japan
    J Med Virol 75:550-8. 2005
    ..Further large-scale studies are warranted to examine the role of amino acid substitutions on IFN resistance specific for steatosis...
  57. ncbi Diabetes enhances hepatocarcinogenesis in noncirrhotic, interferon-treated hepatitis C patients
    Yusuke Kawamura
    Department of Hepatology, Toranomon Hospital, Minato ku, Tokyo, Japan
    Am J Med 123:951-956.e1. 2010
    ..This retrospective cohort study assessed the impact of diabetes mellitus on hepatocarcinogenesis and determined the predictors of hepatocarcinogenesis in noncirrhotic, interferon-treated patients with hepatitis C virus infection...
  58. ncbi Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Hepatology 52:421-9. 2010
    ....
  59. ncbi High-dose interferon alpha-2b induction therapy in combination with ribavirin for Japanese patients infected with hepatitis C virus genotype 1b with a high baseline viral load
    Akihito Tsubota
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    J Gastroenterol 39:155-61. 2004
    ....
  60. ncbi Clinical and virological features of non-breakthrough and severe exacerbation due to lamivudine-resistant hepatitis B virus mutants
    Fumitaka Suzuki
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 78:341-52. 2006
    ..More substitutions in the rt region and the other proteins may be related to the emergence of severe hepatitis caused by lamivudine-resistant virus...
  61. ncbi Factors associated with the virological response of lamivudine-resistant hepatitis B virus during combination therapy with adefovir dipivoxil plus lamivudine
    Tetsuya Hosaka
    Department of Gastroenterology, Toranomon Hospital, 2 2 2 Toranomon, Tokyo 105 8470, Japan
    J Gastroenterol 42:368-74. 2007
    ..The aim of this study was to investigate the factors associated with the response of lamivudine-resistant hepatitis B virus (HBV) during combination therapy with adefovir dipivoxil plus lamivudine...
  62. ncbi Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up
    Hiromi Yatsuji
    Department of Hepatology, Toranomon Hospital, 2 2 2 Toranomon, Minato ku, Tokyo 105 8470, Japan
    J Hepatol 48:923-31. 2008
    ..We studied the long-term efficacy (median follow-up of 28 months) of adefovir (ADV) in combination with lamivudine (LAM) in 132 LAM-resistant Japanese patients with chronic genotype C-dominant hepatitis B virus (HBV) infection...
  63. ncbi Interferon monotherapy for patients with chronic hepatitis C and normal serum aminotransferase levels at commencement of treatment
    Satoshi Mamori
    Department of Gastroenterology, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, 105-8470 Tokyo, Japan
    J Gastroenterol 39:776-82. 2004
    ..CONCLUSIONS: Our data suggest that IFN therapy is effective for patients with normal ALT levels and less than 1 Meq/ml HCV-RNA. Thus, such patients should be considered for curative IFN therapy...
  64. ncbi Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 2a high viral load and virological response to interferon-ribavirin combination therapy
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo 105 0001, Japan
    Intervirology 52:301-9. 2009
    ....
  65. ncbi Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hepatitis B virus infection in Japan
    Fumitaka Suzuki
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Intervirology 46:182-9. 2003
    ..However, the patient cohorts in such studies are relatively small...
  66. ncbi Efficacy of interferon monotherapy in young adult patients with chronic hepatitis C virus infection
    Kiminori Uka
    Department of Gastroenterology, Toranomon Hospital, Minato-ku, Tokyo, Japan
    J Gastroenterol 41:470-5. 2006
    ..Long-term IFN monotherapy may be suitable for young women who desire to become pregnant or those with anemia...
  67. ncbi Efficacy of 6-month interferon therapy in chronic hepatitis B virus infection in Japan
    Fumitaka Suzuki
    Department of Gastroenterology, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, 105-8470, Tokyo, Japan
    J Gastroenterol 39:969-74. 2004
    ..CONCLUSIONS: The response rate to 6-month IFN therapy among HBeAg-positive patients was low. However, young patients may require long-term IFN therapy...
  68. ncbi Favorable efficacy of long-term lamivudine therapy in patients with chronic hepatitis B: an 8-year follow-up study
    Norio Akuta
    Department of Gastroenterology, Toranomon Hospital, 2 2 2 Toranomon, Minato ku, Tokyo 105 0001, Japan
    J Med Virol 75:491-8. 2005
    ..None developed cirrhosis or hepatocellular carcinoma (HCC) during follow-up. Our results suggest that long-term lamivudine therapy improves long-term prognosis, especially when additional treatment for breakthrough hepatitis is used...
  69. ncbi Viral dynamics and pharmacokinetics in combined interferon alfa-2b and ribavirin therapy for patients infected with hepatitis C virus of genotype 1b and high pretreatment viral load
    Akihito Tsubota
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Intervirology 45:33-42. 2002
    ....
  70. ncbi Interferon-alpha for reinfection with hepatitis C virus in two patients with chronic hepatitis C who had responded to previous therapies
    Norio Akuta
    Division of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Dig Dis Sci 48:1654-7. 2003
  71. ncbi The influence of hepatitis B virus genotype on the development of lamivudine resistance during long-term treatment
    Norio Akuta
    Department of Gastroenterology, Toranomon Hospital, 2 2 2 Toranomon, Minato ku, Tokyo 105 0001, Japan
    J Hepatol 38:315-21. 2003
    ..Genotype-dependent development of lamivudine resistance in hepatitis B virus (HBV) has not been reported...
  72. ncbi Mutations of polymerase, precore and core promoter gene in hepatitis B virus during 5-year lamivudine therapy
    Fumitaka Suzuki
    Department of Gastroenterology, Toranomon Hospital, 2 2 2 Toranomon, Minato ku, Tokyo 105 8470, Japan
    J Hepatol 37:824-30. 2002
    ..The aim of this study was to determine the changes in these regions in patients with chronic hepatitis B virus (HBV) infection treated with lamivudine for 5 years...
  73. ncbi Efficacy of interferon monotherapy to 394 consecutive naive cases infected with hepatitis C virus genotype 2a in Japan: therapy efficacy as consequence of tripartite interaction of viral, host and interferon treatment-related factors
    Norio Akuta
    Division of Gastroenterology, Toranomon Hospital, 2 2 2 Toranomon, Minato ku, Tokyo 105 0001, Japan
    J Hepatol 37:831-6. 2002
    ..The mechanism of variable response to interferon (IFN) monotherapy in patients infected with HCV genotype 2a is still unclear. Here we investigated the response in a large group of patients infected with genotype 2a...
  74. ncbi Long-term prognosis by lamivudine monotherapy for severe acute exacerbation in chronic hepatitis B infection: emergence of YMDD motif mutant and risk of breakthrough hepatitis -- an open-cohort study
    Norio Akuta
    Department of Gastroenterology, Toranomon Hospital, 2 2 2 Toranomon, Minato ku, Tokyo 105 0001, Japan
    J Hepatol 38:91-7. 2003
    ..Comparison of long-term prognosis in patients with chronic hepatitis B treated with lamivudine, with or without severe acute exacerbation (SAE)...
  75. ncbi Hepatitis B virus-related hepatocellular carcinogenesis and its prevention
    Kenji Ikeda
    Department of Gastroenterology, Toranomon Hospital, Tokyo, and Okinaka Memorial Institute for Medical Research, Tokyo, Japan
    Intervirology 48:29-38. 2005
    ..026). A significant decrease or loss of serum HBV-DNA stops HCC development, and its sequential analysis could be very useful both in the prediction and early detection of small HCC...
  76. ncbi Virological and biochemical relapse after discontinuation of lamivudine monotherapy for chronic hepatitis B in Japan: comparison with breakthrough hepatitis during long-term treatment
    Norio Akuta
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Intervirology 48:174-82. 2005
    ..CONCLUSION: Our results in Japanese patients with genotype C-dominant hepatitis B suggest that discontinuation of lamivudine monotherapy, and retreatment after the emergence of YMDD mutant should be given attention...
  77. ncbi Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads
    Hitomi Sezaki
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Dig Dis Sci 54:1317-24. 2009
    ..Response to treatment in patients with chronic hepatitis C, with reference to age and gender, has not been examined fully...
  78. ncbi Hepatocarcinogenesis following HCV RNA eradication by interferon in chronic hepatitis patients
    Miharu Hirakawa
    Department of Hepatology, Toranomon Hospital, Tokyo
    Intern Med 47:1637-43. 2008
    ..The aim of the present study was to determine the rate of hepatocarcinogenesis and the risk factor in sustained virological responders...
  79. ncbi Virological outcomes in patients infected chronically with hepatitis B virus genotype A in comparison with genotypes B and C
    Mariko Kobayashi
    Research Institute for Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 78:60-7. 2006
    ..In conclusion, patients persistently infected with HBV genotype A fare better than those with genotype B or C. However, high levels of HBV DNA continue in those in whom HBeAg persists along with fibrosis in the liver...
  80. ncbi Natural history of compensated cirrhosis in the Child-Pugh class A compared between 490 patients with hepatitis C and 167 with B virus infections
    Masahiro Kobayashi
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 78:459-65. 2006
    ....
  81. ncbi Inhibitory effect of branched-chain amino acid granules on progression of compensated liver cirrhosis due to hepatitis C virus
    Masahiro Kobayashi
    Department of Gastroenterology, Toranomon Hospital, 2 2 2 Toranomon, Minato ku, Tokyo, 105 8470, Japan
    J Gastroenterol 43:63-70. 2008
    ..A phase II randomized controlled trial was conducted in patients with compensated liver cirrhosis to investigate the inhibitory effect of branched-chain amino acid (BCAA) granules for oral use (TK-98) on disease progression...
  82. ncbi Long-term outcome of HBV carriers with negative HBe antigen and normal aminotransferase
    Kenji Ikeda
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Am J Med 119:977-85. 2006
    ..To elucidate the incidence of hepatitis activation and hepatocellular carcinogenesis in patients with negative HBe antigen and normal aminotransferase, long-term observation was performed in a retrospective cohort...
  83. ncbi Effect of acute self-limited hepatitis C virus (HCV) superinfection on hepatitis B virus (HBV)-related cirrhosis. Virological features of HBV-HCV dual infection
    Norio Akuta
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Dig Dis Sci 49:281-8. 2004
    ..Our results suggest that the impact of acute HCV infection on chronic HBV infection varies according to HBV virological state...
  84. ncbi Influence of hepatitis C virus subtype on hepatocellular carcinogenesis: a multivariate analysis of a retrospective cohort of 593 patients with cirrhosis
    Kenji Ikeda
    Department of Gastroenterology, Toranomon Hospital, and the Memorial Institute for Medical Research, Tokyo, Japan
    Intervirology 45:71-8. 2002
    ..The influence of hepatitis C virus (HCV) subtypes on hepatocellular carcinogenesis was prospectively investigated...
  85. ncbi Efficacy of lamivudine therapy in elderly patients with chronic hepatitis B infection
    Tomokazu Kawaoka
    Department of Hepatology, Toranomon Hospital, 2 2 2 Toranomon, Tokyo 105 8470, Japan
    J Gastroenterol 42:395-401. 2007
    ..The aim of this study was to evaluate the efficacy of lamivudine therapy in elderly patients with chronic HBV infection...
  86. ncbi Interferon for treatment of breakthrough infection with hepatitis B virus mutants developing during long-term lamivudine therapy
    Fumitaka Suzuki
    Research Institute for Department of Gastroenterology, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo 105-8470, Japan
    J Gastroenterol 37:922-7. 2002
    ....
  87. ncbi Association of amino acid substitution pattern in nonstructural protein 5A of hepatitis C virus genotype2a low viral load and response to interferon monotherapy
    Norio Akuta
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 69:376-83. 2003
    ..Our results suggest that substitution patterns in NS5A in patients with low titer of HCV genotype 2a may affect their response to IFN, but the response to therapy may be affected by mechanisms other than substitutions in this region...
  88. ncbi Amino acid substitutions in the hepatitis C virus core region of genotype 1b are the important predictor of severe insulin resistance in patients without cirrhosis and diabetes mellitus
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 81:1032-9. 2009
    ....
  89. ncbi HBe antigen loss during lamivudine therapy is not caused by mutations in precore and core promoter genes in patients with chronic hepatitis B
    Fumitaka Suzuki
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 70:355-60. 2003
    ..Our data suggested that during lamivudine therapy, core promoter and precore mutations do not influence HBeAg loss or seroconversion but may reduce the viral level upon HBeAg loss or seroconversion...
  90. ncbi Type C-chronic hepatitis patients who had autoimmune phenomenon and developed jaundice during interferon therapy
    Hitomi Sezaki
    Department of Gastroenterology, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo 105-8470, Japan
    J Gastroenterol 38:493-500. 2003
    ..if IFN is expected to be efficacious on the basis of genotype of HCV-RNA level; even if there is acute exacerbation of type-C chronic hepatitis, IFN should be re-administered in the HCV-RNA level has dropped subsequently...
  91. ncbi Clinical characteristics of patients infected with hepatitis B virus genotypes A, B, and C
    Mariko Kobayashi
    Research Institute for Hepatology, Toranomon Hospital, Kawasaki, Japan
    J Gastroenterol 37:35-9. 2002
    ..001) and to have a positive family history of HBV infection (P = 0.0002). CONCLUSIONS: The clinical features of patients with HBV infection in metropolitan Tokyo varied depending on the HBV genotype...
  92. ncbi [HBe antigen and HBe antibody]
    Yasuji Arase
    Department of Gastroenterology, Toranomon Hospital
    Nippon Rinsho 62:124-8. 2004
  93. ncbi Virological and biochemical relapse according to YMDD motif mutant type during long-term lamivudine monotherapy
    Norio Akuta
    Department of Gastroenterology and Liver Research Laboratory, Toranomon Hospital, Tokyo, Japan
    J Med Virol 71:504-10. 2003
    ..Large-scale studies of each mutant type should be conducted in the future to confirm these findings...
  94. ncbi Virological and biochemical features in elderly HCV patients with hepatocellular carcinoma: amino acid substitutions in HCV core region as predictor of mortality after first treatment
    Suguru Ogura
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Intervirology 52:179-88. 2009
    ..The aim of this study was to evaluate the impact of core aa substitutions on mortality in elderly patients...
  95. ncbi Extending combination therapy with peginterferon plus ribavirin for genotype 2 chronic hepatitis C virological responders: a pilot study of 7 cases
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan akuta gi umin ac jp
    Intervirology 53:188-92. 2010
    ..In treatment-resistant patients with genotype 2 chronic hepatitis C the suitable treatment duration is still unclear. The aims were to investigate extending combination therapy with peginterferon plus ribavirin for genotype 2...